Cargando…
Clinical impact of COVID-19 on patients with choroidal neovascularization on intravitreal anti-VEGF therapy
Autores principales: | Agorogiannis, Eleftherios I., Maleedy, Deena, Hakim, Navid, McDaid, David, Silver, Laura, Madhusudhan, Savita, Beare, Nicholas A. V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320719/ https://www.ncbi.nlm.nih.gov/pubmed/34326493 http://dx.doi.org/10.1038/s41433-021-01698-5 |
Ejemplares similares
-
Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to traumatic choroidal rupture
por: Barth, T., et al.
Publicado: (2019) -
Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis
por: Shah, Nikunj J, et al.
Publicado: (2011) -
Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta
por: Rishi, Pukhraj, et al.
Publicado: (2012) -
Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy
por: Rishi, Ekta, et al.
Publicado: (2010) -
Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks
por: Esen, Ebru, et al.
Publicado: (2015)